Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (14628)	12/10/2004 12:48:30 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Sam, I suspect this is purely a humanitarian issue. Not likely to make any meaningful contribution to JNJ even if it becomes widely used world-wide. JNJ is too big and TB patients are too poor. Although I suppose if they get approval in the US they could get some moderately decent sales - don't really know what the incidence of resistant TB in the US is, but perhaps it is growing along with immigration from the former Soviet Union and similar places. Note that the combination of TB and HIV/AIDS is deadly and a growing problem. Peter